HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
HLA typing, demographic and immunological risk factors for nevirapine and efavirenz reactions were studied in a French cohort of HIV patients. Cases with isolated rash were significantly associated with HLA-DRB101 allele. No liver toxicity was observed and no association was detected with the percentage of CD4 T-cells. This study suggests that HLA-DRB101 allele plays an important role in susceptibility to cutaneous reactions associated with nevirapine and efavirenz in HIV patients.
Vitezica
Zulma G
ZG
INSERM, U563, Centre de Physiopathologie de Toulouse Purpan, Toulouse, France.
Milpied
Brigitte
B
Lonjou
Christine
C
Borot
Nicolas
N
Ledger
Terence Niel
TN
Lefebvre
Anne
A
Hovnanian
Alain
A
D000328:Adult; D000368:Aged; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects*; D048588:Benzoxazines / Q000009:adverse effects*; D003521:Cyclopropanes; D003875:Drug Eruptions / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D006684:HLA-DR Antigens / Q000235:genetics*; D059811:HLA-DRB1 Chains; D006801:Humans; D008297:Male; D008875:Middle Aged; D019829:Nevirapine / Q000009:adverse effects*; D011446:Prospective Studies
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; C497841:HLA-DRB1*01 antigen; D019829:Nevirapine; C098320:efavirenz